Trial Profile
A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Sep 2017
Price :
$35
*
At a glance
- Drugs Hepatitis E vaccine recombinant (Primary) ; Recombinant hepatitis E vaccine (Hecolin)
- Indications Hepatitis E
- Focus Adverse reactions; Pharmacodynamics
- 10 Aug 2017 Results published in the Vaccine
- 30 Aug 2016 Status changed from recruiting to completed.
- 12 May 2016 New trial record